Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Patient impact: development of drugs to treat METex14 alterations

Paul Paik, MD, of the Memorial Sloan Kettering Cancer Center, New York, NY, discusses how the development of drugs to treat METex14 alterations may impact lung cancer patients. This interview was recorded at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.